AgNovos Healthcare

AgNovos Healthcare develops proprietary regenerative medical devices targeting local bone loss from osteoporosis and related conditions. Its lead product, the OSSURE™ Local Osteo-enhancement Procedure (LOEP) kit—based on a calcium-based osteoconductive biomaterial—has demonstrated immediate and durable increases in bone density and strength in preclinical and clinical studies. The company has completed several clinical trials including CONFIRM for post-menopausal women with osteoporosis, with additional large-scale studies such as RESTORE underway to support global market access. Their investigational AGN1 LOEP SV kit for vertebral compression fractures has received both Breakthrough Device designation and an Investigational Device Exemption from the FDA.